25N-NB4OMe
A synthetic psychedelic compound
25N-NB4OMe is a synthetic psychedelic compound belonging to the phenethylamine class. It is a derivative of the 2C family of psychedelics, specifically related to 2C-N, and is part of the NBOMe series, which are known for their potent effects at low doses.
Chemical Structure and Properties[edit | edit source]
25N-NB4OMe is chemically known as 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine. It features a phenethylamine core with a bromine atom at the 4-position and methoxy groups at the 2- and 5-positions of the phenyl ring. The N-benzyl substitution is a characteristic feature of the NBOMe series, enhancing its affinity for the 5-HT2A receptor.
Pharmacology[edit | edit source]
25N-NB4OMe acts primarily as a partial agonist at the 5-HT2A receptor, which is the primary target for classical psychedelics such as LSD and psilocybin. The compound's high potency is attributed to the N-benzyl substitution, which increases its binding affinity compared to its 2C counterpart.
Effects[edit | edit source]
The effects of 25N-NB4OMe are similar to other psychedelics, including altered perception of time and space, visual hallucinations, and changes in thought patterns. The onset of effects typically occurs within 30 to 90 minutes after administration, with a duration of action lasting 6 to 10 hours.
Safety and Toxicity[edit | edit source]
As with other NBOMe compounds, 25N-NB4OMe has been associated with a risk of overdose and adverse effects, particularly at higher doses. Users may experience vasoconstriction, hypertension, tachycardia, and in severe cases, seizures or death. Due to its potency, precise dosing is critical to avoid toxicity.
Legal Status[edit | edit source]
The legal status of 25N-NB4OMe varies by country. In some jurisdictions, it may be classified as a controlled substance, while in others, it remains unscheduled. Users should be aware of the legal implications of possessing or distributing this compound in their region.
Research and Applications[edit | edit source]
Research on 25N-NB4OMe is limited, primarily due to its status as a novel psychoactive substance. However, it may be of interest in the study of serotonin receptor pharmacology and the development of new therapeutic agents targeting the 5-HT2A receptor.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
